Chouairi F, Mullan CW, Ahmed A, Bhinder J, Guha A, Miller PE et al (2022) Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation. PLoS ONE 17:e0273111. https://doi.org/10.1371/journal.pone.0273111

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newman JD, Schlendorf KH, Cox ZL, Zalawadiya SK, Powers AC, Niswender KD et al (2022) Post-transplant diabetes mellitus following heart transplantation. J Heart Lung Transplantation 41:1537–1546. https://doi.org/10.1016/j.healun.2022.07.011

Article  Google Scholar 

Huang S, Tamaroff J, Farber-Eger E, Chow N, Siddiqi HK, Brinkley DM et al (2025) Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation. JACC Heart Fail 13:102710. https://doi.org/10.1016/j.jchf.2025.102710

Article  CAS  PubMed  PubMed Central  Google Scholar 

López-Sainz Á, Barge‐Caballero E, Barge‐Caballero G, Couto‐Mallón D, Paniagua‐Martin MJ, Seoane‐Quiroga L et al (2018) Late graft failure in heart transplant recipients: incidence, risk factors and clinical outcomes. Eur J Heart Fail 20:385–394. https://doi.org/10.1002/ejhf.886

Article  PubMed  Google Scholar 

Gami A, Blumenthal RS, McGuire DK, Sarkar S, Kohli P New Perspectives in Management of Cardiovascular Risk Among People With Diabetes. J Am Heart Assoc 2024;13. https://doi.org/10.1161/JAHA.123.034053

Brinker L, Sideris K, Wei G, Singh R, Nevers MR, Hartsell SE et al (2025) Diabetes Therapy With SGLT2i After Heart Transplant. JACC Heart Fail 13:102520. https://doi.org/10.1016/j.jchf.2025.102520

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https://doi.org/10.1136/bmj.n71

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJWV (2022) Cochrane Handbook for Systematic Reviews of Interventions version 6.3, Cochrane, ; 2022

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https://doi.org/10.1136/bmj.i4919

Article  PubMed  PubMed Central  Google Scholar 

Cehic MG, Muir CA, Greenfield JR, Hayward C, Jabbour A, Keogh A et al (2019) Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients. Transpl Direct 5:e450. https://doi.org/10.1097/TXD.0000000000000885

Article  CAS  Google Scholar 

Muir CA, Greenfield JR, MacDonald PS (2017) Empagliflozin in the management of diabetes mellitus after cardiac transplantation. J Heart Lung Transplantation 36:914–916. https://doi.org/10.1016/j.healun.2017.05.005

Article  Google Scholar 

Raven LM, Greenfield JR, Jabbour A, Macdonald PS, Muir CA (2025) Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation. JHLT Open 8:100255. https://doi.org/10.1016/j.jhlto.2025.100255

Article  PubMed  PubMed Central  Google Scholar 

Yen F, Hung Y, Huang J, Hsu C, Cheng W, Hwu C et al (2025) Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes. J Intern Med 297:532–542. https://doi.org/10.1111/joim.20077

Article  CAS  PubMed  Google Scholar 

Lu Y-M, Chang C-Y, Chen M-F, Lu K-H, Chang C-Y, Wei J et al (2025) Are There Any Renoprotective Effects of SGLT2 Inhibitors in Heart Transplant Recipients with Diabetes? Acta Cardiol Sin 41:242–250. https://doi.org/10.6515/ACS.202503_41(2).20241111C

Article  PubMed  PubMed Central  Google Scholar 

Harrington J, Severino A, Yanek L, Fida N, Ishaq F, Al-Saffar F et al (2026) Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in post-heart transplant patients: A multi-center retrospective cohort study. JHLT Open 11:100465. https://doi.org/10.1016/j.jhlto.2025.100465

Article  PubMed  Google Scholar 

Raven LM, Brinker L, Sideris K, Muir CA, Carter S, Beddhu S et al (2025) Sodium glucose cotransporter 2 inhibitor use after heart transplant: Current knowledge and potential applications. Am J Transplant 25:2303–2312. https://doi.org/10.1016/j.ajt.2025.08.013

Article  CAS  PubMed  Google Scholar 

Butt MI, Albalwi RMH, Alnassar N, Alghamdi R. Empagliflozin Use in Cardiac Transplant Patients: Real-world experience from Saudi Arabia Sultan Qaboos Univ Med J 2025;25:91–7. https://doi.org/10.18295/squmj.10.2024.057

de Mattos AM, Olyaei AJ, Bennett WM (2000) Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 35:333–346. https://doi.org/10.1016/S0272-6386(00)70348-9

Article  PubMed  Google Scholar 

Bhat M, Usmani SE, Azhie A, Woo M (2021) Metabolic Consequences of Solid Organ Transplantation. Endocr Rev 42:171–197. https://doi.org/10.1210/endrev/bnaa030

Article  PubMed  Google Scholar 

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S et al (2021) Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiol 6:148. https://doi.org/10.1001/jamacardio.2020.4511

Article  PubMed  PubMed Central  Google Scholar 

Braunwald E (2022) Gliflozins in the Management of Cardiovascular Disease. N Engl J Med 386:2024–2034. https://doi.org/10.1056/NEJMra2115011

Article  CAS  PubMed  Google Scholar 

Custodio JS, Duraes AR, Abreu M, Albuquerque Rocha N, Roever L (2018) SGLT2 inhibition and heart failure—current concepts. Heart Fail Rev 23:409–418. https://doi.org/10.1007/s10741-018-9703-2

Article  CAS  PubMed  Google Scholar 

Wang H, Xie X, Gong G, Huang L, Tang Z (2026) Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients with Diabetes Mellitus Following Heart Transplantation: A Meta-analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01866-4

Article  PubMed  PubMed Central  Google Scholar 

Cahuapaza-Gutierrez NL, Calderon-Hernandez CC, Umeres-Bravo MM, Villavicencio-Escudero TV (2026) Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Transplant Recipients: A Systematic Review and Meta-analyses. Am J Cardiovasc Drugs. https://doi.org/10.1007/s40256-026-00792-x

Article  PubMed  Google Scholar 

Geum MJ, Oh KS, Ah Y-M Sodium–Glucose Cotransporter 2 Inhibitors in Diabetic Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis of Comparative Studies. J Diabetes Res 2026;2026. https://doi.org/10.1155/jdr/8540354

Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M et al Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Reviews 2024;2024. https://doi.org/10.1002/14651858.CD015588.pub2

Cardoso R, Graffunder FP, Ternes CMP, Fernandes A, Rocha AV, Fernandes G et al (2021) SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine 36:100933. https://doi.org/10.1016/j.eclinm.2021.100933

Article  PubMed  PubMed Central  Google Scholar 

Lala A, Beavers C, Blumer V, Brewer L, De Oliveira-Gomes D, Dunbar SB et al (2025) The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology. J Card Fail. https://doi.org/10.1016/j.cardfail.2025.06.013

Article  PubMed  Google Scholar 

Wu M-Z, Guo R, Chandramouli C, Liu L, Tung AM-O, Tsang CT-W et al (2025) Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaf788

Article  PubMed  PubMed Central  Google Scholar